2020

Caspase-9 inhibiting eyedrops rescue physiological and functional retinal vein occlusion damage shown with Phoenix MICRON™, OCT, and focal ERG

In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.

2020

Targeting VEGF164 in Müller cells may be useful to treat retinopathy of prematurity

In Nature’s Scientific Reports, Becker et al use the Phoenix MICRON IV, OCT, and focal ERG to assess the therapeutic value of knocking down a splice variant of VEGF in Müller cells in a model of Retinopathy of Prematurity (ROP). ROP is characterized by delayed vascularization of the retina after disrupted oxygen levels, followed by

2019

Corneal Thickness Analysis using OCT

Corneal images taken with the Phoenix Micron IV OCT used for thickness analysis King et al, a consortium of researchers at a range of institutions, recently used the Phoenix Micron IV OCT to examine corneal thickness in their article, “Genomic locus modulating corneal thickness in the mouse identifies POU6F2 as a potential risk of developing

2019

Characterizing a mutant rat strain with the Phoenix Micron OCT and Ganzfeld ERG

Monai et al characterized the longitudinal retinal degeneration of a rat model of retinitis pigmentosa using the Phoenix Micron OCT to examine retinal layers in live rats and the full field Ganzfeld ERG to test function. The rats have one of the mutations, P23H, that cause retinitis pigmentosa in humans, and are specifically a very